Coya Therapeutics to Host Conference Call Presenting Clinical Data of COYA 302 in Patients with Amyotrophic Lateral Sclerosis (ALS) on March 21, 2023, at 8:00am ET
Txylo.com/10228614

HOUSTON ~ Coya Therapeutics, Inc. (NASDAQ: COYA) announced today that it will host a conference call to present clinical data of its proprietary investigational biologic combination, COYA 302, in patients with Amyotrophic Lateral Sclerosis (ALS). The call will take place on Tuesday, March 21, 2023 at 8:00am ET.

Dr. Stanley Appel, the chair of Coya's Scientific Advisory Board, will provide commentary on the data summarizing work conducted at his lab at Houston Methodist Hospital. Following Dr. Appel's comment's, Dr. Howard Berman, Coya's CEO, and Dr. Adrian Hepner, Coya's CMO, will provide additional comments on the impact of this data on Coya's clinical pipeline and upcoming clinical and regulatory milestones.

The proof-of-concept open-label clinical study is the first-of-its-kind evaluating a dual-mechanism immunotherapy for the treatment of ALS. Patients in the study received investigational treatment for 12 consecutive months and were evaluated for safety and tolerability, Treg function, serum biomarkers of oxidative stress and inflammation, and clinical functioning as measured by the ALSFRS-R scale. The dual-mechanism investigational biologic combination combines low dose Interleukin-2 that is intended to enhance anti-inflammatory regulatory T cell function with a fusion protein that is intended to suppress pro-inflammatory cell function and has been designed to be administered subcutaneously to minimize treatment burden for patients and caregivers.

More on Txylo.com

• SkillGigs, Inc. Announces Hire of Rasha Sammour as Human Resources Director
• Love & Drugs 3 Releases Globally
• Doug Brownridge Joins STS Capital Partners
• CourMed Founder/CEO Derrick L. Miles Featured in CNBC Viral Article on Private Aviation
• 10-4Gear.com Launches New Collection of US Border Patrol and Police Coins

The data from this study will also be presented at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference on March 21st as well. MDA is a voluntary health organization in the United States for people living with muscular dystrophy, ALS, and related neuromuscular diseases that has been leading research efforts for over 70 years in order to empower those affected by these diseases to live longer more independent lives.

Coya Therapeutics is a clinical stage biotechnology company based in Houston TX that is developing multiple therapeutic platforms intended to enhance Treg function including biologics and cell therapies. Their 300 Series product candidates are biologic therapies intended to enhance Treg function and expand Treg numbers with COYA 301 being a cytokine biologic for subcutaneous administration intended to enhance Treg function while COYA 302 being a biologic combination for subcutaneous or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages.

More on Txylo.com

• CSC Motorcycles Announces New Twin Cylinder 650cc Sport Touring Model
• Vincenzo Sannipoli Announces the Release of Sulla vetta del tubo
• Cargill joins Selerant on stage at American Food Innovate 2023
• The In-N-Out Burger Financial Planning Story
• Cash Depot Appoints Tony Gaines as Chief Revenue Officer and Brand Ambassador

Those interested in attending the conference call can dial 888-506-0062 (toll free) or 973-528-0011 (international) using access code 666962 or follow along via webcast link https://www.webcaster4.com/Webcast/Page/2956/47797 . A replay of the call can be accessed by dialing 877-481-4010 (toll free) or 919-882-2331 (international) using passcode 47797 or via webcast link https://www.webcaster4.com/Webcast/Page/2956/47797 .

---

Show All News | Report Violation